De Novo device
Quantra Hemostasis Analyzer
Hemosonics, LLC · Coagulation System For The Measurement Of Whole Blood Viscoelastic Properties (QFR, Class II) · First FDA decision Mar 12, 2019, newest Aug 24, 2023Anemia, clotting and blood disordersSurgical bleeding and hemostasis
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
De Novo pathway
Device trials
2
Naming "Quantra Hemostasis"
MAUDE reports
0
Brand "Quantra Hemostasis", since 2015
PubMed studies
8
Mentioning "Quantra Hemostasis"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Quantra Hemostasis Analyzer
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
K232215 · Decided Aug 24, 2023 · 29 days after receipt
Device type: Coagulation System For The Measurement Of Whole Blood Viscoelastic Properties (QFR) · Laboratory Medicine & Pathology
K230461 · Decided Mar 24, 2023 · 31 days after receipt
Device type: Coagulation System For The Measurement Of Whole Blood Viscoelastic Properties (QFR) · Laboratory Medicine & Pathology
- Quantra Hemostasis Analyzer, QPlus CartridgeNew device typeDe Novo
DEN180017 · Decided Mar 12, 2019 · 344 days after receipt
Device type: Coagulation System For The Measurement Of Whole Blood Viscoelastic Properties (QFR) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Quantra Hemostasis", any status and sponsor, newest update first.
- Quantra Point-of-Care Hemostasis MonitoringPivotal-lookingActive, not recruiting
The Cleveland ClinicAcademic, hospital or other
NCT06328647 · 666 participants (planned) · Start Oct 3, 2024 · Primary completion Dec 31, 2026
Device: POC Quantra QPlus System · For: Bleeding; Hemostatic Disorder
Sites: Cleveland, Ohio
University Hospital, Clermont-FerrandAcademic, hospital or other
NCT05026281 · 80 participants · Start Dec 16, 2021 · Primary completion Jan 31, 2024
Device: Quantra analyzer · For: Anticoagulants and Bleeding Disorders
Sites: Clermont-Ferrand, France; Grenoble, France; Lyon, France · 6 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Quantra Hemostasis", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QFR
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Quantra Hemostasis"[tiab]. The summary above synthesizes these.
- Efficacy of sonorheometry point of the care device in determining low fibrinogen levels in pregnant blood: an invitro dilution and reconstitution study.
Kodali BS, Karuppiah A, Bharadwaj S, et al. · J Clin Monit Comput · 2022Clinical Trial, Research Support, Non-U.S. Gov't
- The quantra hemostasis analyzer compared to thromboelastography (TEG) in the surgical oncologic population: A prospective observational trial.
Idowu O, Ifeanyi-Pillette I, Owusu-Agyemang P, et al. · J Surg Oncol · 2021Observational Study
- Viscoelastic hemostatic assays: Update on technology and clinical applications.
Faraoni D, DiNardo JA · Am J Hematol · 2021Review
- Reference values in healthy children using the Quantra Hemostasis Analyzer, a novel point of care viscoelastic testing device.
Tumber S, Stondell C, Wilson M, et al. · Paediatr Anaesth · 2022
- Questions about COVID-19 associated coagulopathy: possible answers from the viscoelastic tests.
Pavoni V, Gianesello L, Pazzi M, et al. · J Clin Monit Comput · 2022Review
- Comparison of SEER Sonorheometry With Rotational Thromboelastometry and Laboratory Parameters in Cardiac Surgery.
Huffmyer JL, Fernandez LG, Haghighian C, et al. · Anesth Analg · 2016Comparative Study, Observational Study
- A Novel Device for the Evaluation of Hemostatic Function in Critical Care Settings.
Ferrante EA, Blasier KR, Givens TB, et al. · Anesth Analg · 2016Validation Study
- The Efficacy of Fibrinogen Concentrates in Relation to Cryoprecipitate in Restoring Clot Integrity and Stability against Lysis.
Whyte CS, Rastogi A, Ferguson E, et al. · Int J Mol Sci · 2022
Other devices of this type
Also filed under product code QFR.
- QStat CartridgeHemosonics, LLC · 510(k) 2024
- Quantra QPlus SystemHemosonics, LLC · 510(k) 2022
- Quantra QStat CartridgeHemosonics, LLC · 510(k) 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.